- Home
- STTK vs OPXS Comparison
STTK vs OPXS Comparison
Compare STTK & OPXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- OPXS
- Stock Information
- Founded
- STTK 2016
- OPXS 1987
- Country
- STTK United States
- OPXS United States
- Employees
- STTK N/A
- OPXS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- OPXS Electronic Components
- Sector
- STTK Health Care
- OPXS Technology
- Exchange
- STTK Nasdaq
- OPXS Nasdaq
- Market Cap
- STTK 56.8M
- OPXS 45.6M
- IPO Year
- STTK 2020
- OPXS N/A
- Fundamental
- Price
- STTK $1.23
- OPXS $6.39
- Analyst Decision
- STTK Hold
- OPXS
- Analyst Count
- STTK 3
- OPXS 0
- Target Price
- STTK $2.00
- OPXS N/A
- AVG Volume (30 Days)
- STTK 127.4K
- OPXS 18.6K
- Earning Date
- STTK 02-27-2025
- OPXS 02-10-2025
- Dividend Yield
- STTK N/A
- OPXS N/A
- EPS Growth
- STTK N/A
- OPXS 61.76
- EPS
- STTK N/A
- OPXS 0.55
- Revenue
- STTK $6,435,000.00
- OPXS $33,995,000.00
- Revenue This Year
- STTK $313.04
- OPXS N/A
- Revenue Next Year
- STTK N/A
- OPXS N/A
- P/E Ratio
- STTK N/A
- OPXS $11.61
- Revenue Growth
- STTK 382.75
- OPXS 32.49
- 52 Week Low
- STTK $0.94
- OPXS $5.50
- 52 Week High
- STTK $11.76
- OPXS $10.30
- Technical
- Relative Strength Index (RSI)
- STTK 52.10
- OPXS 35.89
- Support Level
- STTK $1.11
- OPXS $6.60
- Resistance Level
- STTK $1.36
- OPXS $6.98
- Average True Range (ATR)
- STTK 0.11
- OPXS 0.30
- MACD
- STTK 0.01
- OPXS 0.07
- Stochastic Oscillator
- STTK 56.67
- OPXS 32.39
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About OPXS Optex Systems Holdings Inc.
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, and light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson and Applied Optics Center Dallas and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor and others.